Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J A Lyons

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Gene Therapy|December 15, 2006
Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in miceJ A Lyons, B J Sheahan, S E Galbraith, et al.
Science (New York, N.Y.)|October 16, 1992
Formation of a gated channel by a ligand-specific transport protein in the bacterial outer membraneJ M Rutz, J Liu, J A Lyons, et al.
Cancer|February 19, 1999
Predictors of local recurrence following excision alone for ductal carcinoma in situS Hetelekidis, L Collins, B Silver, et al.
Neurology|June 10, 2010
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trialR T Naismith, L Piccio, J A Lyons, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Gene Therapy|December 15, 2006
Inhibition of angiogenesis by a Semliki Forest virus vector expressing VEGFR-2 reduces tumour growth and metastasis in miceJ A Lyons, B J Sheahan, S E Galbraith, et al.
Science (New York, N.Y.)|October 16, 1992
Formation of a gated channel by a ligand-specific transport protein in the bacterial outer membraneJ M Rutz, J Liu, J A Lyons, et al.
Cancer|February 19, 1999
Predictors of local recurrence following excision alone for ductal carcinoma in situS Hetelekidis, L Collins, B Silver, et al.
Neurology|June 10, 2010
Rituximab add-on therapy for breakthrough relapsing multiple sclerosis: a 52-week phase II trialR T Naismith, L Piccio, J A Lyons, et al.
Pageof 3